Dr. Bruix Discusses the Application of Regorafenib in HCC

Jordi Bruix, MD
Published: Friday, Apr 28, 2017



Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the application of regorafenib (Stivarga) in hepatocellular carcinoma as opposed to other tumor types.

Prior to its approval in HCC, regorafenib was approved in colorectal cancer and for patients with gastrointestinal stromal tumors (GIST). It was poorly tolerated in colorectal cancer, which made the oncology community question its application.

According to Bruix, it is imperative to consider the population in which this drug is applied. The population of patients with HCC that participated in RESORCE had progressed on sorafenib (Nexavar), adds Bruix, which is instrumental.
 


Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the application of regorafenib (Stivarga) in hepatocellular carcinoma as opposed to other tumor types.

Prior to its approval in HCC, regorafenib was approved in colorectal cancer and for patients with gastrointestinal stromal tumors (GIST). It was poorly tolerated in colorectal cancer, which made the oncology community question its application.

According to Bruix, it is imperative to consider the population in which this drug is applied. The population of patients with HCC that participated in RESORCE had progressed on sorafenib (Nexavar), adds Bruix, which is instrumental.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x